"Designing Growth Strategies is in our DNA"

Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Forecast, 2022-2029

Region : Global | Format: PDF | Report ID: FBI100386

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Prevalence of Multiple Sclerosis - For Key Countries
    2. Regulatory Scenario - For Key Countries
    3. Patent Snapshot, Key Players
    4. New Product Launches
    5. Pipeline Analysis & R&D Investments
    6. Key Industry Developments - Mergers, Acquisitions and Partnerships
    7. Multiple Sclerosis Treatment Cost
    8. Impact of COVID-19 on the Market
  5. Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2018-2029
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2018-2029
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2018-2029
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2018-2029
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. China
      2. India
      3. Japan
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2018-2029
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2018-2029
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. South Africa
      2. GCC
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2021)
    2. Company Profiles (Overview, Product Applications & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Biogen
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Merck KGaA
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Sanofi
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Novartis AG
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. F. Hoffmann-La Roche Ltd.
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. Pfizer Inc.
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      9. Bristol-Myers Squibb Company
        1. Overview,
        2. Product Applications & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
Read Less

Figure 1:  Global Multiple Sclerosis Drugs Market Revenue Breakdown (USD billion, %) by Region, 2021 & 2029

Figure 2:  Global Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2021 & 2029

Figure 3:  Global Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2021 & 2029

Figure 4:  Global Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2021 & 2029

Figure 5:  Global Multiple Sclerosis Drugs Market Value (USD billion), by Region, 2021 & 2029

Figure 6:  North America Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2021 & 2029

Figure 7:  North America Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2021

Figure 8:  North America Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2021 & 2029

Figure 9:  North America Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2021

Figure 10:  North America Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2021 & 2029

Figure 11:  North America Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2021

Figure 12:  North America Multiple Sclerosis Drugs Market Value (USD billion), By Country, 2021 & 2029

Figure 13:  North America Multiple Sclerosis Drugs Market Value Share (%), By Country, 2021

Figure 14:  Europe Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2021 & 2029

Figure 15:  Europe Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2021

Figure 16:  Europe Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2021 & 2029

Figure 17:  Europe Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2021

Figure 18:  Europe Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2021 & 2029

Figure 19:  Europe Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2021

Figure 20:  Europe Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2021 & 2029

Figure 21:  Europe Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2021

Figure 22:  Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2021 & 2029

Figure 23:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2021

Figure 24:  Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2021 & 2029

Figure 25:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2021

Figure 26:  Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2021 & 2029

Figure 27:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2021

Figure 28:  Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2021 & 2029

Figure 29:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2021

Figure 30:  Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2021 & 2029

Figure 31:  Latin America Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2021

Figure 32:  Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2021 & 2029

Figure 33:  Latin America Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2021

Figure 34:  Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2021 & 2029

Figure 35:  Latin America Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2021

Figure 36:  Latin America Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2021 & 2029

Figure 37:  Latin America Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2021

Figure 38:  Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2021 & 2029

Figure 39:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2021

Figure 40:  Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2021 & 2029

Figure 41:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2021

Figure 52:  Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2021 & 2029

Figure 43:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2021

Figure 44:  Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2021 & 2029

Figure 45:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2021

Figure 46:  Global Multiple Sclerosis Drugs Market Share (%), By Company, 2021

Table 1:  Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2018–2029

Table 2:  Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2018–2029

Table 3:  Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2018–2029

Table 4:  Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2018–2029

Table 5:  Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Region, 2018–2029

Table 6:  North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2018–2029

Table 7:  North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2018–2029

Table 8:  North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2018–2029

Table 9:  North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2018–2029

Table 10:  North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country, 2018–2029

Table 11:  Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2018–2029

Table 12:  Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2018–2029

Table 13:  Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2018–2029

Table 14:  Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2018–2029

Table 15:  Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2018–2029

Table 16:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2018–2029

Table 17:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2018–2029

Table 18:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2018–2029

Table 19:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2018–2029

Table 20:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2018–2029

Table 21:  Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2018–2029

Table 22:  Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2018–2029

Table 23:  Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2018–2029

Table 24:  Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2018–2029

Table 25:  Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2018–2029

Table 26:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2018–2029

Table 27:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2018–2029

Table 28:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2018–2029

Table 29:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2018–2029

Table 30:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2018–2029

  • May, 2022
  • 2021
  • 2018-2020
  • 160

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X